SOURCE: Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation

August 31, 2010 08:45 ET

Radient Pharmaceuticals Resumes Collaboration to Advance Its Onko-Sure® In Vitro Diagnostic Cancer Test in the USA

TUSTIN, CA--(Marketwire - August 31, 2010) -  Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today it has resumed collaborations with Mayo Collaborative Services, Inc. to conduct a clinical study for the validation of RPC's US FDA-approved Onko-Sure® in vitro diagnostic (IVD) cancer test as a useful tool in colorectal cancer (CRC) recurrence and treatment monitoring.

Over 1,000 colorectal patient samples with various disease stages will be tested in parallel by RPC and Mayo Clinic to directly compare the results of the Onko-Sure® test with the Carcinoembryonic Antigen (CEA) test. The primary goal of the study is to determine whether Onko-Sure® is more effective than CEA at detecting early stage colorectal cancers. CEA has been reported to misdiagnose a disproportionate number of early stage cancers. Detecting cancer in earlier stages can lead to improved accuracy in the treatment, monitoring and recurrence monitoring of the disease in cancer patients. This head-to-head study is scheduled to be completed in the fourth quarter FY2010 and data generated will be provided to Mayo physicians and investigators for publication in medical journals.

"We are very excited to resume collaboration with Mayo's Validation Support Services team. This marks a critical and potentially market changing milestone for Radient Pharmaceuticals and for our Onko-Sure® IVD cancer test," commented Douglas MacLellan, Chairman and CEO of RPC. "Through this work, we expect to validate the efficacy of RPC's Onko-Sure® test as a critical tool for treatment, monitoring, and/or recurrence monitoring of colorectal cancer suffers."

RPC's Onko-Sure® IVD cancer test is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic (IVD) test used for the detection and monitoring of the treatment and/or recurrence of various types of cancer. The test enables physicians and healthcare professionals to effectively detect and/or monitor certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure® is cleared by the US FDA for detection during colorectal cancer treatment and/or for recurrence monitoring in colorectal cancer patients and by Health Canada for the detection, treatment and/or recurrence monitoring of lung cancer. For more information visit www.onko-sure.com.

RPC Contact Information:
For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company's corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at IR@Radient-Pharma.com or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its Onko-Sure® In Vitro Diagnostic cancer test. The company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve patient outcomes. Radient Pharmaceutical's current Onko-Sure® cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com.

About Mayo Validation Support Services:
Mayo Validation Support Services, an affiliate of Mayo Clinic, based in Rochester, Minnesota and assists pharmaceutical, biotechnology and diagnostic companies in validating the clinical significance of emerging biomarkers and technologies. Mayo's contribution of well-annotated biospecimens and clinical follow-up data support the development of individualized medicine, one of Mayo's strategic initiatives.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Contact Information

  • Radient Pharma Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    Email Contact
    Tel: 206.310.5323